CytomX Therapeutics operates at the clinical forefront of oncology drug development with its proprietary PROBODY technology designed to reduce off-target toxicity through conditionally activated biologics. Despite promising Phase 1 data for lead candidate Varseta-M targeting colorectal cancer, the company’s revenue declined nearly 45% in 2025 alongside widening operating losses, reflecting ongoing high R&D investment and limited commercialization. Sustained cash burn necessitated a $250 million equity raise in early 2026 to finance pipeline advancement. CytomX must balance clinical progression of its pipeline against operational costs and regulatory hurdles before potentially transitioning toward commercialization.